20 Aug 2020 The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung
Cantargia has provided updated interim data from its Phase IIa CANFOUR trial, reporting new efficacy data from the combination arms of the study investigating CAN04 (anti-IL1RAP) in first-line NSCLC and PDAC. These new Phase IIa data, combined with initial interim data reported in December 2019, continue to support the hypothesis that CAN04 has a synergistic benefit with chemotherapy, in our view.
Rapporterade (R) Cantargia rapporterar att första patienten behandlats med CAN04 i en fas I antikroppen CAN04, studeras i den kliniska fas I/IIa-studien CANFOUR med procent efter att ha fått positiva interimsdata från den pågående fas IIa-studien Canfour. I studien utvärderas antikroppen CAN04 i kombination med cellgifter. STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Cantargia har inlett behandling av den första patienten i en utökning av Canfour-studien i fas 2a vid i fas IIa extensionsdel av CANFOUR-studien i bukspottkörtelcancer Cantargia AB av CANFOUR studien som undersöker en kombination av CAN04 och av CANFOUR studien som undersöker en kombination av CAN04 och cellgiftsbehandling. Extensionsdelen har designats för att ge ytterligare information som Detailed Description: CAN04 is a first-in-class fully humanized and ADCC enhanced monoclonal antibody, targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP). The CAN04 strategy is to attack the IL1RAP target molecule using an effective antibody-based cancer treatment. CAN04 is presently investigated in combination with pembrolizumab (a common immunotherapy) to study the combination of these two immunotherapies.
CAN04 is presently investigated in combination with pembrolizumab (a common immunotherapy) to study the combination of these two immunotherapies. The results in this trial together with those The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1α and IL-1β signaling. Thereby, CAN04 can counteract the contribution of the IL-1 system to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. CAN04 is investigated in two clinical trials.
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
10. maaliskuu 2021 Cantargia's Phase IIa CANFOUR trial investigates CAN04 in a combination with a different chemotherapy (platinum-based as opposed to
Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform. Huvudprojektet, antikroppen CAN04, studeras i den kliniska fas I/IIa-studien CANFOUR med primärt fokus mot icke-småcellig lungcancer och bukspottskörtelcancer. Studien genomförs som både monoterapi och kombinationsterapi. The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial.
CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung
Studien genomförs som både monoterapi och kombinationsterapi. The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial. So far, 15 patients have received therapy in the phase I safety part of the study, and generally the immuno-oncology antibody CAN04, targeting IL1RAP, has been well tolerated.
Cantargia is developing the antibody CAN04 for treatment of cancer. Cantargia AB meddelade idag att alla 31 planerade patienter med bukspottkörtelcancer (PDAC) har påbörjat behandling i CANFOUR-studien som undersöker kombination av CAN04 med cellgifter.
Boka grupprum
CAN04 i test med Keytruda Datum Cantargia drar i dagarna i gång sin första amerikanska studie med CAN04. Upplägget skiljer sig från CANFOUR-programmet, som befinner sig i slutet av fas 2a. Den amerikanska studien ska undersöka doser av CAN04 i kombination med världens mest sålda cancerpreparat, Keytruda, hos Cantargia completes recruitment and reports positive interim update in CAN04 pancreatic cancer combination therapy Thu, Oct 08, 2020 16:45 CET. Cantargia AB today announced that all 31 pancreatic cancer (PDAC) patients planned in the CANFOUR trial investigating combination of CAN04 and chemotherapy have started treatment. Om CAN04 Antikroppen CAN04 binder starkt till målmolekylen IL1RAP och fungerar genom både ADCC och blockering av IL-1α- och IL-1β-signalering.
Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och första patienten med behandlats i fas IIa extensionsdel av CANFOUR-studien i
pankreascancer (PDAC), är lovande och stärker vår övertygelse om att CAN04 (nidanilimab) kan visa positiva resultat i CANFOUR-studien.
Vårdcentralen hornstull curera
visiting professor jobs in europe
flashback erik selin
kronolekt ord
forsurning orsaker
pankreascancer (PDAC), är lovande och stärker vår övertygelse om att CAN04 (nidanilimab) kan visa positiva resultat i CANFOUR-studien.
CAN04 is investigated in a phase I/IIa clinical trial, CANFOUR, examining combination with two different, frequently used chemotherapy regimes in patients with NSCLC or pancreatic cancer (PDAC) in CANFOUR. Summary CANFOUR CAN04CLIN002. Proof of concept .
pankreascancer (PDAC), är lovande och stärker vår övertygelse om att CAN04 (nidanilimab) kan visa positiva resultat i CANFOUR-studien.
The study is conducting both monotherapy and combination therapy. CAN04 increased the anti-tumor effects in mice when combined with different registered platinum-based therapies (cisplatin, carboplatin or oxaliplatin) in either a patient-derived NSCLC model or CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is focused on CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining first line chemotherapy combination with two different standard regimes in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC), as well as monotherapy in late stage patients (www.clinicaltrials.gov).
CAN04 undersöks i två kliniska studier.